BINV — BioInvent International AB Share News
0.000.00%
Last trade - 00:00- SEK1.59bn
- SEK1.14bn
- SEK226.50m
Brief: BioInvent: BI-1808 Shows Favorable Safety Profile
Sweden's BioInvent Q1 net sales fall, loss widens
Brief: BioInvent Q1 Sales SEK 13.4 Million
Brief: Bioinvent Achieves Phase 3 Milestone, Eligible For EUR 1 Mln Payment
Sweden's BioInvent posts lower net sales in Q4, focuses on accelerating advanced assets
Brief: BioInvent Q4 Sales SEK 3 Million
Brief: BioInvent Presents Promising Early Data in CTCL
Brief: BioInvent Q3 Sales SEK 3.3 Million
Brief: Transgene, Bioinvent To Present Translational Data And Updated Clinical Results On Armed Oncolytic Virus Bt-001
Europe Research Roundup: Bioinvent, Diasorin, Sandoz
Brief: Bioinvent Q2 Net Revenue SEK 198.1 Million
Brief: Bioinvent Announces Strategic Changes In Portfolio
Brief: BioInvent Q2 Sales SEK 198.1 Million
Brief: Xoma Royalty Buys Mezagitamab Royalty, Milestone Rights Held By Bioinvent For Up To $30 Mln
Brief: BioInvent Gets FDA Fast Track Designation For Bi-1808
Brief: BioInvent Q1 Sales SEK 22.1 Million
Brief: Bioinvent Receives FDA Orphan Drug Designation For Bi-1808
Brief: BioInvent Q4 Sales SEK 21.4 Million
Brief: Bioinvent: Promising Initial Efficacy Data From Triple Combination Arm Of BI-1206, Rituximab And Calquence